Search results
CVS COVID-19 Vaccine Near Columbus OH
www.cvs.comPharmacy LocationBy appointment only2100 East Dublin Granville Road(614) 891-14103355 East Livingston Avenue(614) 237-373760 North Stygler Road(614) 475-20142160 North High Street(614) 294-21051485 Polaris Pkwy(614) 781-09503424 S High Street(614) 491-81374280 Morse Road(614) 473-1123Mar 17, 2022 · Approximately one half of Omicron infections in unvaccinated children and adolescents were asymptomatic. Two doses of Pfizer-BioNTech COVID-19 vaccine reduced the risk of Omicron infection by 31% among children aged 5–11 years and by 59% among persons aged 12–15 years.
Feb 18, 2023 · A three-dose series of the Pfizer COVID-19 vaccine was 73% effective at preventing symptomatic COVID-19 in children ages 6 months to 4 years old, the researchers found.
Feb 15, 2023 · We present results for children 6 months to less than 2 years of age and those 2 to 4 years of age through the data-cutoff dates (April 29, 2022, for safety and immunogenicity and June 17, 2022,...
Mar 3, 2022 · Among adolescents aged 12–17 years during the full study period including pre-Delta, Delta, and Omicron predominant periods, 2-dose VE estimates were higher (76%–83%) 14–149 days after receipt of a second dose, and significantly lower (38%–46%) at ≥150 days postvaccination.
Mar 1, 2022 · An analysis of early data on the effectiveness of the Pfizer/BioNTech COVID-19 vaccine in children and teens found that a third shot, or booster, extended protection against emergency department (ED) and urgent care visits in 16- and 17-year-olds.
Dec 20, 2022 · Some preliminary data showed lower effectiveness from the reduced dose (10 μg) of mRNA vaccine (Pfizer-BioNTech) administered to children of 11 years compared with adolescents aged 12 years receiving a full dose (30 μg). 9 However, vaccine effectiveness in children seems to be lower than in adults (against mild or severe disease), even for those...
Jan 10, 2024 · The study included 526 966 primary schedule vaccinated adolescents. VE against COVID-19–related hospitalization was 72.6% (95% confidence interval [CI], 62.5–82.7) and RD was –2.8 (95% CI, –4.5 to –1.0) per 10 000 vaccinated for BNT162b2 at 6 months of follow-up compared with unvaccinated.
